Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.51 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.50 |
| ▸ | GPR174 | Q9BXC1 | 3/20 | 0.46 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.46 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.46 |
| ▸ | PTPRC | P08575 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 8/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 8/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 7/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 7/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1152 | 0.85 | PTPRC (0.57) | ITGB3ITGA2BPTPRCPTPN1 | |
| SCHEMBL4066744 | 0.85 | PTPRC (0.57) | ITGB3ITGA2BPTPRCPTPN1 | |
| SCHEMBL273663 | 0.85 | PTPRC (0.57) | ITGB3ITGA2BPTPRCPTPN1 | |
| SCHEMBL3626587 | 0.85 | PTPRC (0.57) | ITGB3ITGA2BPTPRCPTPN1 | |
| SCHEMBL19615883 | 0.84 | PTPRC (0.56) | ITGB3ITGA2BPTPRCPTPN1 | |
| Phosphoric Acid SCHEMBL3476886 | 0.84 | PTPRC (0.56) | ITGB3ITGA2BPTPRCPTPN1 | |
| SCHEMBL29567635 | 0.84 | PTPRC (0.56) | ITGB3ITGA2BPTPRCPTPN1 | |
| SCHEMBL29613927 | 0.84 | PTPRC (0.56) | ITGB3ITGA2BPTPRCPTPN1 | |
| Phosphine SCHEMBL28192584 | 0.84 | PTPRC (0.56) | ITGB3ITGA2BPTPRCPTPN1 | |
| SCHEMBL27947556 | 0.84 | PTPRC (0.56) | ITGB3ITGA2BPTPRCPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841257-B2 | Inhibitors of STAT3 and uses thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120035114-A1 | INHIBITORS OF STAT3 AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-02-09 | — | — | US | disclosed |
| WO-2010118309-A2 | INHIBITORS OF STAT3 AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035114-A1 | INHIBITORS OF STAT3 AND USES THEREOF | STAT3, JAK2, STAT6 | ITGB3 1666/4885ITGA2B 2787/4885P2RY10 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.